Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
15.71
Dollar change
+1.38
Percentage change
9.64
%
Index- P/E- EPS (ttm)-6.31 Insider Own30.80% Shs Outstand2.01M Perf Week13.76%
Market Cap32.05M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float1.41M Perf Month16.37%
Income-34.90M PEG- EPS next Q- Inst Own28.70% Short Float0.24% Perf Quarter84.40%
Sales12.50M P/S2.56 EPS this Y- Inst Trans101.46% Short Ratio0.24 Perf Half Y122.84%
Book/sh22.34 P/B0.70 EPS next Y- ROA-48.01% Short Interest0.00M Perf Year81.55%
Cash/sh21.29 P/C0.74 EPS next 5Y29.90% ROE-56.74% 52W Range4.50 - 14.40 Perf YTD67.13%
Dividend Est.- P/FCF- EPS past 5Y- ROI-74.17% 52W High9.10% Beta0.72
Dividend TTM- Quick Ratio7.25 Sales past 5Y0.00% Gross Margin77.27% 52W Low249.11% ATR (14)0.93
Dividend Ex-Date- Current Ratio7.25 EPS Y/Y TTM19.36% Oper. Margin-284.10% RSI (14)71.79 Volatility6.32% 6.17%
Employees74 Debt/Eq0.09 Sales Y/Y TTM- Profit Margin-279.23% Recom2.00 Target Price60.00
Option/ShortNo / Yes LT Debt/Eq0.03 EPS Q/Q-1244.87% Payout- Rel Volume2.58 Prev Close14.33
Sales Surprise- EPS Surprise-15.25% Sales Q/Q- EarningsNov 08 AMC Avg Volume13.72K Price15.71
SMA2016.46% SMA5038.67% SMA20070.82% Trades Volume35,345 Change9.64%
Date Action Analyst Rating Change Price Target Change
Oct-11-21Initiated BofA Securities Buy $11
Sep-15-21Initiated Guggenheim Buy $20
Sep-07-21Initiated Stifel Buy $19
Jan-18-24 09:58AM
08:30AM
Dec-14-23 05:52AM
05:51AM
Nov-08-23 04:05PM
04:05PM Loading…
Aug-09-23 04:05PM
Jun-05-23 08:30AM
May-10-23 04:05PM
Apr-05-23 08:30AM
Mar-28-23 04:59AM
Mar-22-23 04:01PM
Mar-20-23 04:30PM
Jan-04-23 04:41PM
Nov-14-22 04:30PM
Oct-10-22 08:00AM
08:00AM Loading…
Oct-06-22 08:00AM
Sep-26-22 08:00AM
Aug-11-22 08:00AM
Jun-27-22 10:34AM
Jun-13-22 08:00AM
May-24-22 08:00AM
May-18-22 08:00AM
May-16-22 08:00AM
May-11-22 08:00AM
May-05-22 08:00AM
May-02-22 08:00AM
Mar-24-22 08:00AM
Jan-20-22 09:00AM
Jan-10-22 08:00AM
Jan-05-22 08:00AM
04:00PM Loading…
Nov-15-21 04:00PM
08:00AM
08:00AM
Nov-11-21 10:51AM
Nov-05-21 08:00AM
Oct-05-21 04:30PM
Sep-23-21 08:30AM
Aug-11-21 05:30PM
Surrozen, Inc. is a clinical stage biotechnology company. It engages in the business of discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. The company was founded by K. Christopher Garcia and Roeland Nusse on August 12, 2015 and is headquartered in South San Francisco, CA.